Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares are up during Tuesday’s premarket session following positive interim results from one of its Phase 3 trials.
The stock’s rise comes as the company is reportedly making significant strides in its clinical development.
Vertex’s Phase 3 RAINIER Trial Success
Vertex announced that its ongoing Phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy met its primary objective, achieving a 52% reduction from baseline in urine protein to creatinine ratio (UPCR) at Week 36.
Additionally, the trial demonstrated a statistically significant 49.8% UPCR reduction compared to placebo, with 85.1% of patients with baseline hematuria achieving resolution.
The positive data from the trial also showed that patients treated with povetacicept experienced a 77.4% reduction from baseline in serum galactose-deficient IgA1.
The FDA has granted a rolling review of the Biologics License Application for povetacicept, with Vertex planning to complete its full submission by the end of March.
Analyst Sees Clear Win For Vertex
William Blair wrote on Tuesday, “Overall, the Phase III RAINIER proteinuria data is a clear win for Vertex…we believe these data are supportive of a best-in-class product for the BAFF/APRIL inhibitors.”
Analyst Myles Minter increased the probability of success from 70% to 90% ahead of BLA submission completion by the end of March, expected priority review under the voucher program, and potential approval by year-end.
William Blair does not anticipate material revenue from povetacicept in IgAN until 2027, pending reimbursement dynamics and formulary placements.
Technical Analysis
Currently, Vertex Pharmaceuticals is trading 2.2% above its 20-day simple moving average (SMA) and 7.8% above its 100-day SMA, demonstrating longer-term strength. Shares have decreased 7.83% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 44.56, which is considered neutral territory. Meanwhile, MACD is at 0.0109, below its signal line at 3.2118, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $498.00
- Key Support: $454.50
Analyst Consensus & Recent Actions
The stock carries a Buy Rating with an average price target of $523.96. Recent analyst moves include:
- Canaccord Genuity: Hold (Raises Target to $441.00) (Feb. 17)
- Barclays: Overweight (Raises Target to $607.00) (Feb. 17)
- HC Wainwright & Co.: Buy (Raises Target to $591.00) (Feb. 17)
VRTX’s Significant ETF Exposure
- Pacer S&P 500 Quality FCF R&D Leaders ETF (NASDAQ:QFRD): 3.43% Weight
- iShares Biotechnology ETF (NASDAQ:IBB): 8.70% Weight
- VanEck Biotech ETF (NASDAQ:BBH): 9.12% Weight
VRTX Price Action: Vertex Pharmaceuticals shares were up 6.32% at $489.99 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments